NASDAQ : VRAX
Virax Biolabs Group Limited — Key statistics
Healthcare · Biotechnology · United Kingdom
Last price 1.21 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 964.36K
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 964,355 |
| Enterprise Value | -5.14M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 20, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 796,988 |
| Shares Outstanding | 796,988 |
| Shares Change (YoY) | +166.46% |
| Shares Change (QoQ) | +217.37% |
| Owned by Insiders (%) | 4.55% |
| Owned by Institutions (%) | 3.31% |
| Float | 720,719 |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 77.63 |
| Forward PS | n/a |
| PB Ratio | 0.09 |
| P/TBV Ratio | 0.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 9.97 |
| Quick Ratio | 9.55 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -103.60 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -78.65% |
| Return on Assets (ROA) | -54.23% |
| Return on Invested Capital (ROIC) | -58.87% |
| Return on Capital Employed (ROCE) | -83.77% |
| Weighted Average Cost of Capital (WACC) | 11.84% |
| Revenue Per Employee | $478 |
| Profits Per Employee | -$193,221 |
| Employee Count | 26 |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.04 |
Taxes
| Measure | Value |
|---|
| Income Tax | -900,240 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.39 |
| 52-Week Price Change | -91.90% |
| 50-Day Moving Average | 2.18 |
| 200-Day Moving Average | 3.91 |
| Relative Strength Index (RSI) | 27.06 |
| Average Volume (20 Days) | 204,395 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 8,982 |
| Short Previous Month | 6,645 |
| Short % of Shares Out | 1.13% |
| Short % of Float | 1.25% |
| Short Ratio (days to cover) | 0.05 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 12,423 |
| Gross Profit | 7,690 |
| Operating Income | -6.40M |
| Pretax Income | -5.93M |
| Net Income | -5.02M |
| EBITDA | -6.05M |
| EBIT | -6.40M |
| Loss Per Share | -$12.64 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 6.52M |
| Total Debt | 414,387 |
| Net Cash | 6.10M |
| Net Cash Per Share | $7.66 |
| Equity (Book Value) | 7.33M |
| Book Value Per Share | 13.08 |
| Working Capital | 6.14M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -4.62M |
| Capital Expenditures | -255,831 |
| Depreciation & Amortization | 351,581 |
| Net Borrowing | 4.30M |
| Free Cash Flow | -4.88M |
| FCF Per Share | -$6.12 |
Margins
| Measure | Value |
|---|
| Gross Margin | 61.90% |
| Operating Margin | -51,515.17% |
| Pretax Margin | -47,753.55% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -166.46% |
| Shareholder Yield | n/a |
| Earnings Yield | -1,044.63% |
| FCF Yield | -505.80% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 26, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -4.82 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |